STOCK TITAN

Lifestance Health Group, Inc. Stock Price, News & Analysis

LFST Nasdaq

Welcome to our dedicated page for Lifestance Health Group news (Ticker: LFST), a resource for investors and traders seeking the latest updates and insights on Lifestance Health Group stock.

LifeStance Health Group, Inc. (LFST) provides investors and industry observers with timely access to corporate developments through this centralized news hub. Track official press releases, regulatory filings, and strategic announcements from one of the nation's leading outpatient mental healthcare providers.

Key resources include: Earnings reports detailing financial performance, partnership announcements with healthcare networks, expansions of clinical services, and leadership updates. This curated collection serves as a primary source for understanding LFST's operational milestones and market positioning.

All content reflects the company's focus on evidence-based behavioral healthcare and its commitment to expanding access through innovative care models. Regular updates ensure stakeholders stay informed about developments in teletherapy advancements, clinical research collaborations, and regulatory compliance matters.

Bookmark this page for direct access to LFST's verified corporate communications, eliminating the need to search multiple sources. Check back frequently for updates on operational metrics, facility expansions, and other material events shaping the company's trajectory in mental healthcare.

Rhea-AI Summary

LifeStance Health (NASDAQ: LFST), a major outpatient mental healthcare provider, reported strong Q2 2025 financial results. Revenue increased 11% to $345.3 million, driven by higher visit volumes and clinician growth. The company's clinician base grew 11% to 7,708 clinicians, with a net addition of 173 clinicians in Q2.

The company significantly reduced its net loss to $3.8 million from $23.3 million year-over-year, while achieving record free cash flow of $56.6 million. Adjusted EBITDA grew 19% to $34.0 million. For FY 2025, LifeStance reiterated revenue guidance of $1.40-1.44 billion and raised Adjusted EBITDA expectations to $140-150 million.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.03%
Tags
-
Rhea-AI Summary

LifeStance Health (NASDAQ:LFST) released a comprehensive survey revealing that 83% of Americans are experiencing "stressflation" - mental health impacts from financial stress driven by inflation and economic uncertainty. The study highlights a concerning trend where 60% of respondents are deterred from seeking mental health care due to financial constraints, up from 58% in 2024.

Key findings show that 47% of respondents have skipped therapy sessions due to cost, with millennials and Gen Z being most affected. However, there's a positive shift in care continuity, with 33% of patients returning to therapy within a week after a cost-related break in 2025, compared to just 8% in 2024. The survey also revealed that 93% of Americans view mental health care as equally important as physical health care.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.72%
Tags
none
-
Rhea-AI Summary

LifeStance Health Group (NASDAQ: LFST), a leading outpatient mental health care provider, has scheduled its second quarter 2025 earnings release and conference call. The company will release its Q2 2025 financial results before market open on August 7, 2025, followed by a live earnings conference call at 8:30 a.m. Eastern Time.

Investors can join the call using the domestic dial-in number 1-800-715-9871 or international number 1-646-307-1963 with conference ID 1294873. A live audio webcast and related materials will be available through the Events and Presentations section of LifeStance's Investor Relations website, with a replay accessible after the call.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-4.52%
Tags
conferences earnings
Rhea-AI Summary

LifeStance Health Group (NASDAQ: LFST), a leading provider of outpatient mental health care, announced its participation in the 46th Annual Goldman Sachs Healthcare Conference in Miami, Florida. CEO Dave Bourdon and CFO Ryan McGroarty will present on Tuesday, June 10, 2025, at 10:40 a.m. Eastern time. The presentation, moderated by Jamie Perse, will be available via live webcast on the company's investor relations website, with a replay accessible after the event.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-2.15%
Tags
conferences
-
Rhea-AI Summary

LifeStance Health (LFST) has appointed Vaughn Paunovich as its new Chief Technology Officer, effective June 9, 2025. Paunovich, who brings over 25 years of healthcare technology experience, will lead the company's end-to-end technology strategy. He previously served as EVP, Enterprise Platforms at Amwell and held leadership roles at UnitedHealth Group, including CIO of Optum Health.

Paunovich succeeds Pablo Pantaleoni, who is stepping down after joining in 2020 and leading the company's digital transformation efforts. The new CTO will focus on improving patient and clinician experience, increasing access to mental health services, and implementing scalable technologies aligned with LifeStance's mission of delivering virtual and in-person outpatient mental health care.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-2.21%
Tags
none
-
Rhea-AI Summary

National Veterinary Associates (NVA) has announced key board appointments ahead of its planned IPO, naming Ken Burdick as Executive Chairman and Dr. Mike McFarland as Director. Burdick brings over 40 years of healthcare experience and currently serves as Executive Chairman at LifeStance Health (NASDAQ: LFST). He previously led WellCare Health Plans as CEO, delivering strong performance in revenue and profit margins before its acquisition by Centene Corporation.

Dr. McFarland contributes more than 40 years of veterinary healthcare expertise, including 11 years in senior leadership at Zoetis, Inc. and previous roles at Pfizer Animal Health. Greg Hartmann will remain on the board as a director, maintaining his investment in the company.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-15.88%
Tags
IPO management
Rhea-AI Summary
LifeStance Health Group (NASDAQ: LFST) reported strong Q1 2025 financial results, marking its first profitable quarter as a public company. Revenue increased 11% to $333.0 million, driven by higher visit volumes and improved revenue per visit. The company achieved a net income of $0.7 million, compared to a net loss of $21.1 million in Q1 2024. The clinician base grew 10% to 7,535, with visit volumes increasing 10% to 2.1 million. Adjusted EBITDA rose 25% to $34.6 million. LifeStance maintained its full-year 2025 guidance, expecting revenue between $1.40-1.44 billion and Adjusted EBITDA of $130-150 million. The company ended Q1 with $134.3 million in cash and $276.3 million in net long-term debt.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-15.88%
Tags
-
Rhea-AI Summary

LifeStance Health Group (NASDAQ: LFST), a major outpatient mental health care provider, has scheduled its first quarter 2025 earnings release and conference call. The company will release Q1 2025 earnings before market opening on Wednesday, May 7, 2025, followed by a live earnings conference call at 8:30 a.m. Eastern Time.

Investors can participate by dialing 1-800-715-9871 (domestic) or 1-646-307-1963 (international) using conference ID 6060781. A real-time audio webcast will be available through the Events and Presentations section of LifeStance's Investor Relations website, with related materials posted before the call. A replay will be accessible afterward on the same platform.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.49%
Tags
conferences earnings
-
Rhea-AI Summary

LifeStance Health released a survey revealing concerning trends in social media's impact on mental health self-diagnosis. The study found that 29% of Americans self-diagnose mental health conditions based on social media content, with only 47% of these individuals consistently seeking professional guidance.

The survey highlighted that 54% of respondents encounter mental health misinformation weekly on social media, while 23% seek mental health advice on these platforms. Among generations, Gen Z (50%) and millennials (38%) lead in self-diagnosis rates.

Key findings show 26% of respondents check social media within five minutes of waking up, and 76% find the idea of a digital detox appealing. The study also revealed that 40% of respondents frequently encounter clinical terms like "trauma" and "narcissist" on social media, with 32% reporting that such content has led them to question their relationships.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.44%
Tags
none
Rhea-AI Summary

LifeStance Health Group (Nasdaq: LFST) announced significant leadership changes, with Dave Bourdon appointed as the new CEO effective March 3, succeeding Ken Burdick who will transition to Executive Chairman. Bourdon, who joined as CFO in 2022, brings over two decades of healthcare and mental health industry experience.

Ryan McGroarty, with 25 years of healthcare experience including 15 years in CFO roles, will become the new Chief Financial Officer effective March 17. Under Burdick's leadership since September 2022, LifeStance has met or exceeded expectations for nine consecutive quarters.

Bourdon previously served as CFO of Magellan Health and held positions at Cigna, while McGroarty comes from Help at Home where he served as CFO and previously held multiple CFO roles at Cigna.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
3.06%
Tags
management

FAQ

What is the current stock price of Lifestance Health Group (LFST)?

The current stock price of Lifestance Health Group (LFST) is $5.41 as of August 18, 2025.

What is the market cap of Lifestance Health Group (LFST)?

The market cap of Lifestance Health Group (LFST) is approximately 2.1B.
Lifestance Health Group, Inc.

Nasdaq:LFST

LFST Rankings

LFST Stock Data

2.12B
136.33M
8.22%
92.98%
2.06%
Medical Care Facilities
Services-health Services
Link
United States
SCOTTSDALE